Showing posts with label multiresistant. Show all posts
Showing posts with label multiresistant. Show all posts
Tuesday, May 18, 2010
The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab (Avastin)
CONCLUSIONS:
Single agent bevacizumab has activity in ovarian cancer patients. Pre-treatment serum VEGF seems to have predictive value.
Subscribe to:
Posts
(
Atom
)
